AI-based liquid biopsy may detect liver fibrosis, cirrhosis and chronic disease signals
Researchers at Johns Hopkins Kimmel Cancer Center have developed an AI-based liquid biopsy test that can detect early liver fibrosis and cirrhosis. The test uses genome-wide cell-free DNA fragmentation patterns and machine-learning algorithms to identify disease-specific signatures, potentially allowing for early intervention and improved patient outcomes.
Researchers at Johns Hopkins Kimmel Cancer Center have created a liquid biopsy test using AI and genome-wide cell-free DNA fragmentation patterns. The test can detect early liver fibrosis and cirrhosis. It was developed using whole-genome sequencing and machine-learning algorithms. The test analyzed DNA from 1,576 people with liver disease. It can detect early liver disease with high sensitivity. Early detection can make a significant difference in patient outcomes. The test has the potential to identify underlying health conditions that can lead to cancer development.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.